universal sound design: Presentation on Research Results on Difficulty of Hearing Speech Due to Tools for Preventing Droplet-Based Infection
The Laboratory of Hearing Cognition of universal sound design inc. (hereafter “LHC,” HQ: Minato-ku, Tokyo, Japan, President and CEO: Shinichiro Nakaishi), a company aiming to create, through R&D on its high-resolution Sonic Brain® acoustic technologies, a society universally capable of hearing, has performed a joint survey with the Tokyo Metropolitan Industrial Technology Research Institute (hereafter, “TIRI”) on Speech Damping Due to Tools for Preventing Droplet-Based Infection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201224005002/en/
Measurement Results (Graphic: Business Wire)
The purpose of the study was to understand the difficulties present in hearing when using masks, face shields, acrylic barriers, etc., to prevent the spread of COVID-19. This was accomplished by analyzing differences in sound pressure levels when masks, face shields, acrylic barriers, etc., were used and were not used. The results of the survey showed marked damping in frequency bands that affect hearing of consonants when an acrylic barrier was used, and, when a face shield was used, there was an unnatural amplification of the middle register and a decrease in speech clarity.
Measurements & Methods
Audio playback: Broadband noise played through mouth simulator (speaker) placed in mouth of a mannequin (HATS)
Measurements: Measurements made by microphone placed at entrance to ear canal of right ear of listener
Frequency analysis method: One-third octave band analysis
Evaluation method: Evaluation of differences in sound pressure from results of using acrylic barriers to prevent droplet-based infection, masks, and face shields compared with control
*Control: nothing is worn by speaker and no acrylic barrier is used.
With regard to these results, Dr. Masafumi Nakagawa (Professor, International University of Health and Welfare) commented that:
“A damping of 5db is observed at 2000Hz and above when only a mask is worn. This means that the power behind consonant sounds like “t,” “sh,” and “h” is halved, which in turn means that a listener may not hear a consonant or be unable to differentiate between words like “he” and “she.”
“Shields cause similar damping at 2000Hz, but also have an amplifying effect at 800 to 1500Hz. We tend to think that increased volume is a good thing, but if a vowel’s second formant (f2) is emphasized, it can make it more difficult to differentiate between vowels.
“Wearing both a shield and a mask reduces clarity of consonants and the unnatural emphasis of a vowel’s second formant (f2) can lead to mistakes in hearing sounds like “ha” and “a” and being unable to differentiate between “he” and “she.” Being unable to hear consonants makes it difficult to hear numbers, and this can create problems at checkout because the listener needs to pay attention to the display on the register and is unable to communicate with the shop staff, which should instead be one reason to enjoy shopping.
“The maximum damping effect is 10dB, which means that if you use familiar words, speak slowly, enunciate, etc., you can still minimize any discrepancies even when wearing a mask or shield.
“Coronavirus was initially thought to have been transmitted via droplets, but we are now hearing from recent research that measures against aerosols are also necessary. This makes frequent ventilation necessary when using masks and shields, and seeing people for longer than 15 minutes should be avoided.”
The difficulty in hearing caused by the use of masks, face shields, and barriers is of an even greater level for people with difficulty hearing and hearing impairments. Being unable to hear increases stress and a sense of isolation, and so now it is important to think about communication support and systems that can enable anyone to hear.
comuoon® tabletop communication support system
comuoon® is a tabletop communication support system that achieves a new paradigm for conversation support by allowing the speaker, not the listener, to improve how well their speech can be heard. Instead of focusing on the issues facing existing devices like hearing aids that place the burden of accommodation on the listener, comuoon® instead converts what the speaker says into something much easier for the listener to hear and understand, making for improved conversation.
Frequency bands that affect speech clarity are understood to be those at 1,000Hz and above. comuoon® utilizes its proprietary speaker and innovative construction to provide improved fidelity between 1,000 and 10,000Hz.
The benefits of comuoon® in speech discrimination for hearing impaired were presented from a neuroscientific standpoint at the 14th Annual World Congress of Brain Mapping and Therapeutics and the 118th Annual Meeting of the ORL Society of Japan, where it was explained that clarity, not volume, is necessary when speaking with a person with a hearing impairment. comuoon® can be used not only as a tool to help the hearing impaired, but also as a tool for hearing rehabilitation.
Laboratory of Hearing Cognition, universal sound design inc.
The Laboratory of Hearing Cognition conducts research on the effects of super-high resolution sound technologies on the human body.
Collaborative research on the effects of super-high resolution sound on the human body has been performed with a variety of universities, including Kyushu University, as well as other laboratories, medical facilities, and nursing facilities. The Laboratory also developed Sonic Brain®, a technology that makes it easier for the brain to understand speech. The Laboratory is currently involved in hearing frailty awareness through its Hearing Cognition Check app that helps visualize the user’s cognitive abilities to hear words and helps check for early-stage hearing loss.
For General Inquires:
universal sound design inc. Tel: +81-120-033-553
For Inquiries on this Press Release
universal sound design PR Office – Yui Komiyama
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bentley Systems Brings Infrastructure Digital Twins to NVIDIA Omniverse12.4.2021 19:00:00 CEST | Press release
GTC21 – Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced that it is developing applications using the NVIDIA Omniverse platform for photorealistic, real-time visualization and simulation of digital twins of massive-scale industrial and civil infrastructure projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005214/en/ Image courtesy of Houston Waterworks Team (a Joint Venture of Jacobs Engineering Group, Inc. and CDM Constructors, Inc.) Bentley Systems has extended the Bentley iTwin platform to integrate with NVIDIA Omniverse to provide a graphics pipeline for AI-enhanced, real-time visualization, and simulation of infrastructure digital twins. This integration allows engineering-grade, millimeter-accurate digital content to be visualized with photorealistic lighting and environmental effects on multiple devices including web browsers, workstations, tabl
QCT Unveils Optimized Accelerated Server to Boost High-Performance Workloads12.4.2021 19:00:00 CEST | Press release
Quanta Cloud Technology (QCT), a global data center solution provider, today announced a new addition to its broad portfolio of NVIDIA-Certified SystemsTM with its QuantaGrid D43N-3U. This server complements QCT’s existing high-performance QuantaGrid and QuantaPlex family of servers, while enabling customers the ability to leverage the latest next-generation NVIDIA Tensor Core GPUs for advanced AI workloads, including those that run on virtualized infrastructure with the NVIDIA AI Enterprise software suite. NVIDIA Tensor Core GPUs on QCT systems are built on the rich ecosystem of AI frameworks from the NVIDIA NGC catalog, CUDA-X libraries, over 2.3 million developers, and over 1,800 GPU-optimized applications to help enterprises solve the most critical challenges in their business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005024/en/ QuantaGrid_D43N-3U (Photo: Business Wire) “Utilizing NVIDIA accelerated computing
Mavenir Launches 5G Hyperconverged Edge AI Solution for Enterprise & Telco Market Based on NVIDIA Platforms12.4.2021 19:00:00 CEST | Press release
Mavenir, the industry’s only end-to-end cloud-native Network Software Provider and a leader in accelerating software network transformation for communications service providers (CSPs), announced today the launch of an AI-on-5G Hyper Converged Edge solution working in close collaboration with NVIDIA. Mavenir has developed this unique solution, based on NVIDIA’s hardware and software technologies, enabling Enterprises & Telcos to implement AI-on-5G applications for many promising verticals such as Manufacturing, Mining, and Healthcare that cover Industry 4.0 applications, including Industrial Internet of Things (IIoT), Intelligent Video Analytics (IVA) and Extended Reality (XR) and Gaming use cases. The use cases can be around remote and immersive collaboration, precision robotics control, people safety, intrusion detection, smart connected factories, real-time manufacturing component defect detection and proactive maintenance using near real-time analytics of sensor data. 5G enables an
Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent12.4.2021 17:04:00 CEST | Press release
Merck, a leading science and technology company, today announced key clinical advancements for berzosertib (M6620), an investigational, potent and selective ataxia telangiectasia and Rad3-related (ATR) inhibitor. Berzosertib is the leading asset in the company’s DNA damage response (DDR) inhibitor program and one of the most advanced ATR inhibitors in oncology clinical development industry-wide. Results from a Phase II proof-of-concept study conducted by the US National Cancer Institute (NCI) (NCT02487095)* and published in Cancer Cell showed that berzosertib in combination with the chemotherapy topotecan resulted in an objective response rate (ORR) of 36% among patients with relapsed small cell lung cancer (SCLC), including durable responses among a majority of responding patients with platinum-resistant disease.1 The NCI is also conducting a separate Phase II trial of berzosertib in combination with topotecan versus topotecan monotherapy in SCLC that has relapsed (NCT03896503)* which
Loomis Sayles Welcomes Susan Sieker as Chief Financial Officer12.4.2021 16:15:00 CEST | Press release
Loomis, Sayles & Company, an affiliate of Natixis Investment Managers, announced today that Susan Sieker has joined Loomis Sayles as executive vice president and chief financial officer (CFO). She also joins the Loomis Sayles Board of Directors. Susan reports to Kevin Charleston, chairman and chief executive officer of Loomis Sayles, and will oversee the finance organization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005613/en/ Susan joins Loomis Sayles from Cambridge Associates, where she was the chief financial officer and oversaw financial planning and analysis, treasury, accounting operations, financial reporting, payroll and taxes. Prior to joining Cambridge Associates in 2012, Susan served in a variety of finance and risk leadership roles at Brinker International, including vice president and treasurer, vice president of global infrastructure, vice president of benefits, vice president of business assurance
Alira Health Strengthens Its Growth Strategy With a $35M Funding, Led by Creadev12.4.2021 15:00:00 CEST | Press release
Alira Health (www.alirahealth.com), a leading international advisory firm dedicated to advancing healthcare and life sciences, announced it has closed a $35M equity financing led by Creadev, an evergreen investment company backed by the Mulliez family. This new partnership will help accelerate the firm’s growth strategy, focused on merging pharmaceutical, medical and digital technologies development with medical care through a patient-centric approach. “I would like to thank our team of investors for joining our mission to enable healthcare transformation. Their investment positions us to change the way life sciences advisory services are delivered,” said Gabriele Brambilla, Chief Executive Officer and Co-Founder of Alira Health. “We are building a powerful continuum of services that spans the product and solutions development life cycle, supported by the recent additions of our patient engagement, real-world evidence and advanced analytics practices. This financing allows us to advanc
KD Pharma Acquires Phytoextract and CBD Manufacturing Assets12.4.2021 14:45:00 CEST | Press release
The KD Pharma Group has acquired the manufacturing assets of a Swiss-based cannabinoid manufacturer. The assets give KD Pharma access to technology for producing Active Pharmaceutical Ingredients (APIs) based on phytocannabinoids and other plant extracts. The technology further expands KD’s lipid technology portfolio and can be used in combination with KD’s other fractionation and separation technologies. “KD Pharma is a leader in lipid technology focused primarily on omega-3s, but our technology suite has applications in other lipid sources like cannabinoids,” said Oscar Groet, CEO of the KD Pharma Group. “We have committed to expanding our technology portfolio to develop APIs from cannabinoids and plant extracts,” Groet continued, “and these assets give KD Pharma additional pathways to develop new products for this emerging market.” The KD Pharma Group has also licensed a novel extraction method from Herbolea Biotech S.r.l. and expects to have a complete, licensed cGMP manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom